ArticleNeuro-oncology advances
Survival outcomes and clinical characteristics of brain metastases from prostate cancer: A single-center analysis.
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Brain metastases (BrM) from prostate cancer (PC) are rare. This study sought to evaluate their prevalence, clinical features, treatment modalities, and survival outcomes. Methods: From a database of BrM patients, we analyzed 28 cases of prostate cancer treated at our center between 2008 and 2023. Results: BrM from PC comprised 0.7% of cases. The majority of patients had high-risk features at PC diagnosis: median prostate-specific antigen (PSA) at diagnosis was 65.5 ng/ml (range: 3.9-784.7 ng/ml), 82% were Gleason grade group ≥ 4, and 68% had perineural invasion (PNI). At BrM diagnosis, 79% were castrate-resistant. Most patients had concurrent metastases, including bone (94%), lymph nodes (63%), or lung (6%). Fifty percent presented with a single brain lesion, and the median Graded Prognostic Assessment (GPA) score was 1.5 (range: 0.5-2.5). Patients commonly had radiographic brain edema (57%) and neurological symptoms (54%), whereas only 7% had seizures. Median overall survival (OS) was 9.4 months (95% CI: 4.8-14.8 months) after BrM diagnosis. An upward trend in OS was observed with higher GPA ( Conclusion: BrMs from prostate cancer are rare and predominantly occur in patients with advanced, castrate-resistant disease, often accompanied by other metastases. This analysis enhances our understanding of the disease trajectory and informs treatment discussions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.